查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1992807

囊腫纖維化醫療設備市場：按產品類型、分銷管道、最終用戶、治療方法、組件和患者類型分類的全球市場預測，2026 年至 2032 年

Cystic Fibrosis Devices Market by Product Type, Distribution Channel, End User, Modality, Component, Patient Type - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，囊腫纖維化治療設備市場價值將達到 35.7 億美元，到 2026 年將成長至 39.9 億美元，到 2032 年將達到 76.3 億美元，複合年成長率為 11.43%。

主要市場統計數據
基準年 2025 35.7億美元
預計年份：2026年 39.9億美元
預測年份 2032 76.3億美元
複合年成長率 (%) 11.43%

一個權威性的囊腫纖維化醫療設備生態系統框架，將臨床需求、技術進步和交付模式連結起來，從而推動長期治療效果。

囊腫纖維化仍然是一種複雜的多器官疾病，需要採用綜合方法進行呼吸照護、診斷和長期治療管理。儘管分子療法的進步改變了許多患者的臨床病程，但持續降低發病率仍然依賴有效的基於器械的策略，以實現藥物向肺部的輸送、氣道清除、監測和支持性護理。目前，醫療設備涵蓋了從最佳化臨床決策的診斷平台到旨在最佳化藥物沉積、提高用藥依從性和患者舒適度的治療輸送系統。隨著治療模式從間歇性住院轉向持續居家管理，醫療設備的設計、連結性和使用者體驗正成為創新的前沿領域。

肺部輸送、感測、數位整合和分散式護理等領域的突破性進展如何融合，正在重塑醫療設備的優先事項和臨床路徑。

隨著肺部給藥科學、數位醫療和護理模式的進步融合，囊腫纖維化醫療設備領域正經歷著一場變革。吸入技術的創新使得藥物能夠更有效地輸送到周邊氣道，而新型霧化器設計和乾粉系統則減輕了患者的負擔，提高了用藥依從性。同時，感測器的微型化和嵌入式分析功能的增強，正將以往被動的醫療設備轉變為主動的資料來源，為個人化治療方案的調整和遠端監測策略提供資訊。這些技術變革與更廣泛的醫療去中心化趨勢相輔相成。居家治療、線上後續觀察和專業藥局服務正在減少病人對急診機構的依賴，並重新定義醫療監管與病人自主權之間的關係。

評估 2025 年美國關稅對整個醫療設備價值鏈的影響，包括零件採購、製造地和商業策略的重組。

美國在2025年實施的新關稅為支持囊腫纖維化醫療設備生產和分銷的全球供應鏈帶來了新的複雜性。某些零件和成品進口關稅的提高，導致依賴專用泵浦、高精度感測器和客製化閥門的醫療設備總體成本上升。為應對這項挑戰，原始設備製造商 (OEM) 和契約製造正在加快關鍵製造流程的本地化、供應商多元化以及產品重新設計，以在保持臨床準確性的同時降低零件的複雜性。這些調整旨在緩解短期利潤壓力，同時確保符合監管要求並保障患者護理的持續進行。

將產品類型、分銷管道、最終用戶、模式、組件和患者群體與策略設計和商業化方案聯繫起來的詳細細分分析。

在所有用於治療囊腫纖維化的醫療器材中，深入了解市場區隔趨勢對於最佳化產品設計、臨床證據和市場進入策略至關重要。依產品類型分析，市場可分為支援臨床決策的診斷平台和用於輸送治療藥物的肺部給藥系統。肺部給藥系統又細分為乾粉吸入器、吸入器和霧化器等，每種類型在劑量穩定性、維持負擔和易用性方面各有優劣，以滿足不同肺功能患者的需求。吸入器可進一步分為定量吸入器和緩霧吸入器。定量吸入器體積小巧、操作簡便，而緩霧吸入器產生的氣溶膠則較為溫和，可能對某些患者族群較有益。霧化器技術也涵蓋多種結構。由於噴射式霧化器具有成熟的臨床親和性，因此仍被廣泛使用；篩孔式噴霧器霧化器具有便攜性和高效性；超音波霧化器高功率，適用於特定的治療情況。

美洲、歐洲、中東和非洲以及亞太地區的區域趨勢和戰略意義決定了監管、商業和營運選擇。

區域趨勢對囊腫纖維化治療設備的監管路徑、報銷框架和實際應用有顯著影響。在美洲，由臨床經驗豐富的中心和專業藥房組成的成熟網路支持著新型給藥平台的快速部署，而支付方的審查和採購流程則要求提供強力的衛生經濟學證據和清晰的臨床療效證明。隨著企業應對關稅衝擊並努力縮短前置作業時間，跨境生產能力和近岸外包在美洲地區日益凸顯。

投資於能夠使主要企業脫穎而出並創造囊腫纖維化治療領域永續競爭優勢的策略行動和能力。

在囊腫纖維化治療醫療設備領域，主要企業正攜手應對幾項策略挑戰，這些挑戰將決定最終的贏家。首先，優先開發將精準肺內給藥與嵌入式感測和連接功能相結合的整合解決方案的企業，正在創造更強的價值提案。這是因為臨床醫生和支付者越來越期望醫療設備能夠產生可操作的數據，以支持治療依從性和療效監測。其次，採用模組化設計和靈活製造系統的製造商能夠更快地應對零件短缺、關稅波動和當地市場需求，從而在不穩定的供應環境中獲得韌性優勢。

醫療設備製造商和醫療保健領導者的實用策略重點，以確保在囊腫纖維化治療中實現穩健的採購、快速的部署和可衡量的臨床價值。

產業領導者應採取重點突出、切實可行的優先事項，將技術潛力轉化為永續的臨床和商業性成功。首先，設計模組化且組件通用的醫療器械，以便在不影響醫療設備性能的前提下，快速更換供應商和遷移區域製造地。這種方法可以降低關稅相關成本波動帶來的風險，並縮短供應商和醫療機構的補貨時間。其次，整合感測和連接功能，產生具有臨床意義的指標，並使這些指標與支付方的證據要求保持一致。這確保了報銷討論基於以患者為中心的治療結果，而不僅僅是醫療設備的功能。

我們嚴謹的混合方法研究框架，結合了對臨床醫生和供應鏈相關人員的初步訪談以及系統性的二次文獻回顧和檢驗，確保了實用性和基於證據的見解。

本研究採用混合方法，將初步質性研究結果與嚴謹的二次分析結合，透過三角驗證的方式，全面了解囊腫纖維化醫療設備的使用環境。初步研究包括對呼吸科醫生、呼吸治療師、採購負責人、專科藥劑師和醫療設備工程師進行結構化訪談，以了解使用者的實際需求、採購限制和技術權衡。除了訪談外，研究人員還對診所和居家照護機構進行實地考察和觀察研究，以檢驗可用性假設並識別工作流程整合的挑戰。

策略結論強調，模組化設計、連接性、證據產生和適應性經營模式是囊腫纖維化醫療設備成功的關鍵。

總之，囊腫纖維化醫療設備的現狀正處於一個轉折點，技術創新、不斷發展的醫療服務模式和不斷變化的政策壓力在此交匯融合。成功的醫療設備不僅能夠給藥或測量生理數據，更將融入治療路徑中，成為藥物依從性、監測和臨床決策支援的可靠促進者。價格趨勢、區域監管差異以及支付方日益成長的期望等多重壓力，使得敏捷性、循證實踐和以患者為中心的設計成為永續策略的基石。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：囊腫纖維化醫療設備市場：依產品類型分類

  • 診斷
  • 肺部輸送
    • 乾粉吸入器
    • 吸入器
      • 定量吸入器
      • 緩霧吸入器
    • 噴霧器
      • 噴射式霧化器
      • 篩孔式噴霧器
      • 超音波霧化器

第9章：囊腫纖維化醫療設備市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房
  • 專業醫療中心

第10章：囊腫纖維化醫療設備市場：依最終用戶分類

  • 診所
  • 居家照護
  • 醫院

第11章：囊腫纖維化醫療設備市場：依治療方式分類

  • 侵入性
  • 非侵入性

第12章：囊腫纖維化醫療設備市場：依組件分類

  • 泵浦
    • 蠕動幫浦
    • 注射式幫浦
  • 感應器
    • 流量感測器
    • 壓力感測器
  • 閥門

第13章：依病患類型囊腫纖維化醫療設備市場

  • 成人版
  • 兒童

第14章：囊腫纖維化醫療設備市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：囊腫纖維化醫療設備市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章：囊腫纖維化醫療設備市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國囊腫纖維化醫療設備市場

第18章：中國囊腫纖維化醫療設備市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • AlgiPharma AS
  • AstraZeneca plc
  • Baxter International plc
  • Boehringer Ingelheim International GmbH
  • Chiesi Farmaceutici SpA
  • Drive DeVilbiss Healthcare, LLC
  • Electromed, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • Insmed Incorporated
  • Koninklijke Philips NV
  • Medtronic plc
  • Monaghan Medical Corporation
  • Novartis AG
  • PARI GmbH
  • Pfizer Inc.
  • Pharmaxis Ltd.
  • PTC Therapeutics Inc.
  • Sionna Therapeutics
  • Smiths Medical, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Thayer Medical Corporation
  • Vertex Pharmaceuticals Incorporated
  • Viatris Inc
Product Code: MRR-1A1A064C001D

The Cystic Fibrosis Devices Market was valued at USD 3.57 billion in 2025 and is projected to grow to USD 3.99 billion in 2026, with a CAGR of 11.43%, reaching USD 7.63 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.57 billion
Estimated Year [2026] USD 3.99 billion
Forecast Year [2032] USD 7.63 billion
CAGR (%) 11.43%

An authoritative framing of the cystic fibrosis device ecosystem that connects clinical needs, technological advances, and delivery models driving long-term care outcomes

Cystic fibrosis remains a complex, multisystem disease that requires an integrated approach to respiratory care, diagnostics, and long-term therapy management. Advances in molecular therapeutics have changed the clinical course for many patients, yet durable morbidity reduction continues to rely on effective device-based strategies for pulmonary delivery, airway clearance, monitoring, and supportive care. The device landscape spans diagnostic platforms that refine clinical decision making and therapeutic delivery systems designed to optimize deposition, dosing adherence, and patient comfort. As treatment paradigms shift from episodic hospital care to continuous home-based management, device design, connectivity, and user experience have risen to the forefront of innovation.

Against this backdrop, manufacturers and health systems must navigate a confluence of technological innovation, evolving reimbursement models, and tightening regulatory expectations. The interplay between product usability, clinical outcomes, and supply-chain resilience now determines adoption velocity more than ever before. Consequently, stakeholders are evaluating devices not just as hardware, but as integrated care enablers that link diagnostics, inhaled therapies, monitoring sensors, and data analytics to deliver measurable patient benefit. This introduction frames the critical domains that follow, emphasizing the strategic implications for developers, payers, and providers in an era where device performance, patient-centric design, and system-level integration decide clinical and commercial success.

How converging breakthroughs in pulmonary delivery, sensing, digital integration, and care decentralization are reshaping device priorities and clinical pathways

The cystic fibrosis device landscape is undergoing transformative shifts driven by converging advances in pulmonary delivery science, digital health, and care delivery models. Innovations in inhalation technology are enabling more efficient targeting of distal airways, while novel nebulizer designs and dry powder systems are reducing patient burden and improving adherence. Concurrently, sensor miniaturization and embedded analytics are turning traditionally passive devices into active data sources that inform personalized treatment adjustments and remote monitoring strategies. These technological transitions are complemented by a broader move toward decentralizing care: home-based therapies, virtual follow-up, and specialty pharmacy fulfillment are reducing the dependence on acute care settings and redefining the relationship between clinician oversight and patient autonomy.

Regulatory and reimbursement landscapes are also evolving to reflect the clinical value of integrated device-diagnostic solutions, which in turn stimulates investment in combination products and interoperable platforms. Additionally, supply-chain optimization and component-level sourcing decisions are reshaping manufacturing footprints, prompting companies to reconsider vertical integration and design for manufacturability. As stakeholders respond to these shifts, strategic priorities are emerging around human factors engineering, interoperability standards, and evidence generation that ties device use to meaningful clinical endpoints. Ultimately, this confluence of engineering advances, care model innovation, and policy movement is creating a market environment where agility, cross-disciplinary collaboration, and robust clinical validation are the most reliable predictors of sustained adoption.

Assessment of the 2025 United States tariff impacts that have reshaped component sourcing, manufacturing footprints, and commercial strategies across the device value chain

The imposition of new United States tariff measures in 2025 has introduced a new layer of complexity into the global supply chains that underpin cystic fibrosis device manufacturing and distribution. Increased import duties on select components and finished goods have translated into higher landed costs for devices that rely on specialized pumps, precision sensors, and custom valves. In response, OEMs and contract manufacturers have accelerated efforts to localize critical manufacturing steps, diversify supplier bases, and redesign products for reduced parts complexity where clinical fidelity can be preserved. These adjustments aim to mitigate near-term margin pressure while maintaining regulatory compliance and continuity of care for patients.

Downstream effects on distributors and payers are also material. Hospital procurement teams and specialty pharmacies face tighter negotiations as suppliers pass through cost increases, which may influence purchasing cycles and inventory strategies. Meanwhile, manufacturers are reassessing pricing models and commercial terms to protect access without undermining investment in R&D. The tariffs have also highlighted the strategic value of modular device architectures that permit regional sourcing of subassemblies, enabling companies to shift production in response to tariff schedules with less disruption.

Crucially, the tariff landscape has implications beyond cost. It has spurred renewed attention to supply-chain visibility, contract flexibility, and contingency planning. Companies investing in dual-sourcing strategies and strategic stocking arrangements are better positioned to preserve clinical supply continuity and maintain customer trust. At the same time, the policy-induced cost pressure is encouraging collaboration between industry and payers to demonstrate the downstream economic value of devices through reduced hospitalizations and improved long-term outcomes. In sum, tariffs are accelerating structural changes in how devices are designed, sourced, and commercialized, with lasting implications for competitiveness and patient access.

In-depth segmentation analysis connecting product types, distribution channels, end users, modalities, components, and patient cohorts to strategic design and commercialization choices

A granular understanding of segmentation dynamics is essential for tailoring product design, clinical evidence, and go-to-market approaches across the cystic fibrosis device continuum. When analyzed by product type, the landscape divides into diagnostic platforms that support clinical decision making and pulmonary delivery systems that enable therapeutic deposition. Within pulmonary delivery, submodalities include dry powder inhalers, inhalers, and nebulizers, and each submodality carries distinct trade-offs in dose consistency, maintenance burden, and usability for patients with variable pulmonary function. Inhaler formats further bifurcate into metered dose inhalers and soft mist inhalers, with metered dose options offering compactness and legacy familiarity while soft mist approaches provide gentler aerosol generation that can benefit certain patient cohorts. Nebulizer technology also spans multiple architectures; jet nebulizers remain widely used due to established clinical familiarity, mesh nebulizers present advantages in portability and efficiency, and ultrasonic nebulizers deliver high output useful in specific therapeutic contexts.

Distribution channel segmentation reveals differentiated adoption pathways and service expectations across hospital pharmacies, online pharmacies, retail pharmacies, and specialty centers. Each channel introduces unique requirements for packaging, patient education, returns management, and contract terms, which in turn affect lifecycle support and adherence programs. End user segmentation-clinics, home care, and hospitals-further shapes device requirements. Devices intended for home care must prioritize ease of use, durability, and remote monitoring capabilities, whereas hospital and clinic deployments emphasize sterilization, workflow integration, and interoperability with electronic medical records.

Modality distinctions between invasive and non-invasive approaches create separate regulatory and operational considerations. Invasive devices demand more rigorous sterile manufacturing and procedural training, whereas non-invasive technologies must excel in ergonomics and patient adherence to be effective in a home setting. Component-level segmentation highlights pumps, sensors, and valves as critical subsystems; pumps can be delivered as peristaltic designs or syringe-based mechanisms depending on dosing precision needs, while sensors commonly include flow sensors and pressure sensors that inform both clinician decision making and closed-loop control strategies. Finally, patient-type segmentation into adult and pediatric cohorts drives divergent human factors requirements, device sizing, and dosing regimens. Collectively, these segmentation lenses create a mosaic of product and commercial imperatives that must be reconciled to deliver clinically meaningful and commercially viable offerings.

Regional dynamics and strategic implications across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine regulatory, commercial, and operational choices

Regional dynamics exert a major influence on regulatory pathways, reimbursement frameworks, and the practicalities of deploying cystic fibrosis devices. In the Americas, centers of clinical expertise and well-established specialty pharmacy networks support rapid adoption of novel delivery platforms, while payer scrutiny and procurement procedures require robust health-economic evidence and clear demonstrations of real-world outcomes. Cross-border manufacturing capacity and nearshoring initiatives in the Americas have become more prominent as companies respond to tariff shocks and aim to shorten lead times.

Europe, Middle East & Africa presents a heterogeneous regulatory and reimbursement environment characterized by varying national health technology assessment processes and procurement norms. In this region, centralized clinical data packages that address diverse regulatory expectations are especially valuable. Local partnerships with specialty centers and training programs can accelerate clinician acceptance, particularly where hospital-based infusion and nebulization services remain concentrated. Meanwhile, capacity building in some Middle Eastern and African markets requires targeted support for cold chain logistics, clinician training, and patient education to enable home-based therapy expansion.

Asia-Pacific encompasses a broad spectrum of maturity levels, from markets with advanced device uptake and domestic manufacturing capabilities to emerging markets where adoption is constrained by infrastructure and reimbursement gaps. In leading Asia-Pacific markets, agile regulatory systems and strong contract manufacturing ecosystems provide opportunities for scale and innovation. Conversely, in developing healthcare systems across the region, digital health and mobile-enabled care models can act as force multipliers, improving follow-up, adherence monitoring, and supply distribution for home-based management. Taken together, regional variation underscores the necessity of adaptive commercial strategies and regulatory intelligence that align product configurations with local clinical practice and health system incentives.

Strategic behaviors and capability investments that distinguish leading device companies and create durable competitive advantage in cystic fibrosis care

Leading companies in the cystic fibrosis device arena are coalescing around several strategic imperatives that differentiate winners from the rest of the field. First, firms prioritizing integrated solutions that couple precise pulmonary delivery with embedded sensing and connectivity are creating stickier value propositions, as clinicians and payers increasingly expect devices to generate actionable data that supports adherence and outcome monitoring. Second, manufacturers that embrace modular design and flexible manufacturing can respond more rapidly to component shortages, tariff changes, and local market requirements, giving them a resilience advantage in turbulent supply environments.

Partnerships and ecosystem plays have emerged as critical accelerants for both product development and market access. Collaborations between device developers, diagnostic providers, and digital health companies enable combined evidence generation strategies that tie device use to measurable clinical endpoints. Additionally, strategic alliances with specialty pharmacies and home-care providers expand distribution reach and patient support capabilities. Companies investing in robust post-market surveillance and real-world evidence programs are better positioned to negotiate reimbursement and demonstrate value over the product lifecycle.

Finally, talent and capability investments in regulatory affairs, health economics, and human-centered design are proving decisive. Organizations that combine clinical trial expertise with deep user-experience research are producing devices that meet regulatory expectations while simultaneously improving adoption among pediatric and adult patient populations. These cumulative capabilities define the competitive frontier and provide a template for companies seeking sustainable differentiation.

Actionable strategic priorities for device makers and healthcare leaders to ensure resilient sourcing, rapid adoption, and measurable clinical value in cystic fibrosis care

Industry leaders should adopt a set of targeted, actionable priorities to translate technological potential into sustained clinical and commercial success. First, design devices with modularity and component commonality to enable rapid vendor substitution and regional manufacturing shifts without compromising clinical performance. This approach reduces exposure to tariff-induced cost volatility and shortens time-to-replenish for suppliers and providers. Second, integrate sensing and connectivity features that produce clinically relevant metrics, and align those metrics with payer evidence needs so that reimbursement discussions are grounded in patient-centered outcomes rather than device features alone.

Third, develop differentiated distribution strategies tailored to the expectations of hospital pharmacies, online pharmacies, retail pharmacies, and specialty centers, investing in training programs and patient support services that enhance adherence and reduce device-related complications. Fourth, prioritize dual-product development tracks that address both adult and pediatric usability constraints, ensuring that human factors testing is embedded early in the design process. Fifth, cultivate partnerships with home-care organizations and specialty centers to validate workflows and co-create education materials that enable safe and effective home administration. Finally, strengthen regulatory and health-economic capabilities to expedite approvals and build compelling value narratives that resonate with payers and procurement teams. By acting on these recommendations, organizations can increase resilience, accelerate adoption, and align product innovation with the operational realities of modern cystic fibrosis care.

A rigorous mixed-methods research framework combining primary clinician and supply-chain interviews with systematic secondary review and validation to ensure practical, evidence-based insights

This research synthesis is grounded in a mixed-methods approach that triangulates primary qualitative insights with rigorous secondary analysis to create a comprehensive understanding of the cystic fibrosis device environment. Primary research included structured interviews with pulmonologists, respiratory therapists, procurement officers, specialty pharmacists, and device engineers to capture real-world user needs, procurement constraints, and technical trade-offs. These conversations were supplemented by site visits and observational studies in clinic and home-care settings to validate usability assumptions and capture workflow integration challenges.

Secondary research encompassed a systematic review of peer-reviewed clinical literature, regulatory guidance documents, and public filings to contextualize therapeutic trends and device safety considerations. Supply-chain mapping used import-export data and manufacturing intelligence to trace component sourcing pathways and identify critical nodes susceptible to disruption. Findings were validated through an iterative process involving expert advisory reviews and cross-stakeholder workshops to reconcile divergent perspectives and stress-test tactical recommendations.

Limitations of the methodology include potential sampling bias in primary interviews and the rapidly evolving nature of device regulation and tariff policy, which require ongoing monitoring. To mitigate these constraints, the study employed purposive sampling across geographies and stakeholder types and incorporated sensitivity analyses in supply-chain scenarios. The result is a robust, actionable evidence base designed to inform strategic decision making without relying on single-source assumptions.

Strategic conclusion emphasizing how modular design, connectivity, evidence generation, and adaptive commercial models will determine success in cystic fibrosis devices

In closing, the cystic fibrosis device landscape is at an inflection point where technical innovation intersects with changing care delivery models and evolving policy pressures. Devices that succeed will do more than deliver medication or measure physiology; they will embed themselves into care pathways as trusted enablers of adherence, monitoring, and clinical decision support. The combined pressures of tariff dynamics, regional regulatory diversity, and heightened payer expectations make agility, evidence generation, and patient-centric design the pillars of sustainable strategy.

Stakeholders who focus on modularity, connectivity, and strong ecosystem partnerships can both mitigate near-term operational risks and capture longer-term opportunities to improve outcomes across adult and pediatric populations. Ultimately, a pragmatic blend of engineering excellence, clinical validation, and adaptable commercial models will determine which innovations translate into meaningful improvements in patient care. This synthesis provides a strategic foundation for leaders seeking to navigate the path ahead and convert insight into impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cystic Fibrosis Devices Market, by Product Type

  • 8.1. Diagnostic
  • 8.2. Pulmonary Delivery
    • 8.2.1. Dry Powder Inhalers
    • 8.2.2. Inhalers
      • 8.2.2.1. Metered Dose Inhalers
      • 8.2.2.2. Soft Mist Inhalers
    • 8.2.3. Nebulizers
      • 8.2.3.1. Jet Nebulizers
      • 8.2.3.2. Mesh Nebulizers
      • 8.2.3.3. Ultrasonic Nebulizers

9. Cystic Fibrosis Devices Market, by Distribution Channel

  • 9.1. Hospital Pharmacies
  • 9.2. Online Pharmacies
  • 9.3. Retail Pharmacies
  • 9.4. Specialty Centers

10. Cystic Fibrosis Devices Market, by End User

  • 10.1. Clinics
  • 10.2. Home Care
  • 10.3. Hospital

11. Cystic Fibrosis Devices Market, by Modality

  • 11.1. Invasive
  • 11.2. Non Invasive

12. Cystic Fibrosis Devices Market, by Component

  • 12.1. Pumps
    • 12.1.1. Peristaltic Pumps
    • 12.1.2. Syringe Pumps
  • 12.2. Sensors
    • 12.2.1. Flow Sensors
    • 12.2.2. Pressure Sensors
  • 12.3. Valves

13. Cystic Fibrosis Devices Market, by Patient Type

  • 13.1. Adult
  • 13.2. Pediatric

14. Cystic Fibrosis Devices Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Cystic Fibrosis Devices Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Cystic Fibrosis Devices Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Cystic Fibrosis Devices Market

18. China Cystic Fibrosis Devices Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbbVie Inc.
  • 19.6. AlgiPharma AS
  • 19.7. AstraZeneca plc
  • 19.8. Baxter International plc
  • 19.9. Boehringer Ingelheim International GmbH
  • 19.10. Chiesi Farmaceutici S.p.A.
  • 19.11. Drive DeVilbiss Healthcare, LLC
  • 19.12. Electromed, Inc.
  • 19.13. F. Hoffmann-La Roche Ltd.
  • 19.14. Gilead Sciences, Inc.
  • 19.15. Insmed Incorporated
  • 19.16. Koninklijke Philips N.V.
  • 19.17. Medtronic plc
  • 19.18. Monaghan Medical Corporation
  • 19.19. Novartis AG
  • 19.20. PARI GmbH
  • 19.21. Pfizer Inc.
  • 19.22. Pharmaxis Ltd.
  • 19.23. PTC Therapeutics Inc.
  • 19.24. Sionna Therapeutics
  • 19.25. Smiths Medical, Inc.
  • 19.26. Teva Pharmaceutical Industries Ltd.
  • 19.27. Thayer Medical Corporation
  • 19.28. Vertex Pharmaceuticals Incorporated
  • 19.29. Viatris Inc

LIST OF FIGURES

  • FIGURE 1. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CYSTIC FIBROSIS DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COMPONENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES CYSTIC FIBROSIS DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA CYSTIC FIBROSIS DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY DIAGNOSTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY DIAGNOSTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PULMONARY DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PULMONARY DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PULMONARY DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PULMONARY DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY DRY POWDER INHALERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY DRY POWDER INHALERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY DRY POWDER INHALERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY INHALERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY INHALERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY INHALERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY METERED DOSE INHALERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY METERED DOSE INHALERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY METERED DOSE INHALERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SOFT MIST INHALERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SOFT MIST INHALERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SOFT MIST INHALERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY NEBULIZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY NEBULIZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY NEBULIZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY JET NEBULIZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY JET NEBULIZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY JET NEBULIZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY MESH NEBULIZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY MESH NEBULIZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY MESH NEBULIZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY ULTRASONIC NEBULIZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY ULTRASONIC NEBULIZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY ULTRASONIC NEBULIZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SPECIALTY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SPECIALTY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY INVASIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY INVASIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY INVASIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY NON INVASIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY NON INVASIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY NON INVASIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PUMPS, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PERISTALTIC PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PERISTALTIC PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PERISTALTIC PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SYRINGE PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SYRINGE PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SYRINGE PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SENSORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SENSORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SENSORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SENSORS, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY FLOW SENSORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY FLOW SENSORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY FLOW SENSORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PRESSURE SENSORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PRESSURE SENSORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PRESSURE SENSORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY VALVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY VALVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY VALVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PULMONARY DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS CYSTIC FIBROSIS DEVICES MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS CYSTIC FIBROSIS DEVICES MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS CYSTIC FIBROSIS DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS CYSTIC FIBROSIS DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS CYSTIC FIBROSIS DEVICES MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PUMPS, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SENSORS, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PULMONARY DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PUMPS, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SENSORS, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PULMONARY DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PUMPS, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SENSORS, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PULMONARY DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PUMPS, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SENSORS, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PULMONARY DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE CYSTIC FIBROSIS DEVICES MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE CYSTIC FIBROSIS DEVICES MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE CYSTIC FIBROSIS DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE CYSTIC FIBROSIS DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE CYSTIC FIBROSIS DEVICES MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PUMPS, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SENSORS, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PULMONARY DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST CYSTIC FIBROSIS DEVICES MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST CYSTIC FIBROSIS DEVICES MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST CYSTIC FIBROSIS DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST CYSTIC FIBROSIS DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST CYSTIC FIBROSIS DEVICES MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PUMPS, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SENSORS, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PULMONARY DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PUMPS, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SENSORS, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PULMONARY DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC CYSTIC FIBROSIS DEVICES MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC CYSTIC FIBROSIS DEVICES MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC CYSTIC FIBROSIS DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC CYSTIC FIBROSIS DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC CYSTIC FIBROSIS DEVICES MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PUMPS, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SENSORS, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PULMONARY DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN CYSTIC FIBROSIS DEVICES MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN CYSTIC FIBROSIS DEVICES MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN CYSTIC FIBROSIS DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN CYSTIC FIBROSIS DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN CYSTIC FIBROSIS DEVICES MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PUMPS, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SENSORS, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. GCC CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. GCC CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. GCC CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PULMONARY DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 210. GCC CYSTIC FIBROSIS DEVICES MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 211. GCC CYSTIC FIBROSIS DEVICES MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 212. GCC CYSTIC FIBROSIS DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 213. GCC CYSTIC FIBROSIS DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. GCC CYSTIC FIBROSIS DEVICES MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 215. GCC CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 216. GCC CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PUMPS, 2018-2032 (USD MILLION)
  • TABLE 217. GCC CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SENSORS, 2018-2032 (USD MILLION)
  • TABLE 218. GCC CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PULMONARY DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION CYSTIC FIBROSIS DEVICES MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION CYSTIC FIBROSIS DEVICES MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION CYSTIC FIBROSIS DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION CYSTIC FIBROSIS DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION CYSTIC FIBROSIS DEVICES MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PUMPS, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SENSORS, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PULMONARY DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS CYSTIC FIBROSIS DEVICES MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS CYSTIC FIBROSIS DEVICES MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS CYSTIC FIBROSIS DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS CYSTIC FIBROSIS DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS CYSTIC FIBROSIS DEVICES MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PUMPS, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SENSORS, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. G7 CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. G7 CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. G7 CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PULMONARY DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 246. G7 CYSTIC FIBROSIS DEVICES MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 247. G7 CYSTIC FIBROSIS DEVICES MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 248. G7 CYSTIC FIBROSIS DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 249. G7 CYSTIC FIBROSIS DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 250. G7 CYSTIC FIBROSIS DEVICES MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 251. G7 CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 252. G7 CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PUMPS, 2018-2032 (USD MILLION)
  • TABLE 253. G7 CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SENSORS, 2018-2032 (USD MILLION)
  • TABLE 254. G7 CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. NATO CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. NATO CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. NATO CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PULMONARY DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 258. NATO CYSTIC FIBROSIS DEVICES MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 259. NATO CYSTIC FIBROSIS DEVICES MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 260. NATO CYSTIC FIBROSIS DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 261. NATO CYSTIC FIBROSIS DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 262. NATO CYSTIC FIBROSIS DEVICES MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 263. NATO CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 264. NATO CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PUMPS, 2018-2032 (USD MILLION)
  • TABLE 265. NATO CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SENSORS, 2018-2032 (USD MILLION)
  • TABLE 266. NATO CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. GLOBAL CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES CYSTIC FIBROSIS DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED STATES CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PULMONARY DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES CYSTIC FIBROSIS DEVICES MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES CYSTIC FIBROSIS DEVICES MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED STATES CYSTIC FIBROSIS DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES CYSTIC FIBROSIS DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES CYSTIC FIBROSIS DEVICES MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED STATES CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PUMPS, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SENSORS, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED STATES CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA CYSTIC FIBROSIS DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 281. CHINA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PULMONARY DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 284. CHINA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 285. CHINA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 286. CHINA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 287. CHINA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 288. CHINA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PUMPS, 2018-2032 (USD MILLION)
  • TABLE 290. CHINA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY SENSORS, 2018-2032 (USD MILLION)
  • TABLE 291. CHINA CYSTIC FIBROSIS DEVICES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)